Elevance Health (ELV) Reports Q1 Earnings: What Key Metrics Have to Say

Elevance Health (ELV) reported $48.77 billion in revenue for the quarter ended March 2025, representing a year-over-year increase of 15.4%. EPS of $11.97 for the same period compares to $10.64 a year ago.The reported revenue represents a surprise of +5.95% over the Zacks Consensus Estimate of $46.03 billion. With the consensus EPS estimate being $11.21, the EPS surprise was +6.78%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Elevance Health performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Total Medical Membership: 45.83 million versus 46.24 million estimated by 15 analysts on average. Medical Membership - Medicaid: 8.86 million versus the 15-analyst average estimate of 8.89 million. Medical Membership - Medicare - Medicare Supplement: 876 thousand versus the 15-analyst average estimate of 866.49 thousand. Medical Membership - Commercial Risk-Based - Employer Group Risk-Based: 3.64 million versus the 15-analyst average estimate of 3.75 million. Revenues- Premiums: $40.89 billion compared to the $38.70 billion average estimate based on 16 analysts. The reported number represents a change of +14.5% year over year. Revenues- Service fees: $2.07 billion versus $2.13 billion estimated by 16 analysts on average. Compared to the year-ago quarter, this number represents a -0.4% change. Revenues- Net investment income: $590 million versus the 16-analyst average estimate of $461.32 million. The reported number represents a year-over-year change of +26.9%. Revenues- Product revenue: $5.81 billion versus $5.11 billion estimated by 16 analysts on average. Compared to the year-ago quarter, this number represents a +29.1% change. Total operating revenue- Carelon Services: $6.54 billion versus the 14-analyst average estimate of $5.87 billion. The reported number represents a year-over-year change of +63%. Total operating revenue- CarelonRx: $10.12 billion versus $9.40 billion estimated by 14 analysts on average. Compared to the year-ago quarter, this number represents a +25.4% change. Total operating revenue- Health Benefits: $41.43 billion versus the 14-analyst average estimate of $39.82 billion. The reported number represents a year-over-year change of +11.2%. Total operating revenue- Carelon: $16.65 billion versus the 14-analyst average estimate of $15.27 billion. The reported number represents a year-over-year change of +37.9%. View all Key Company Metrics for Elevance Health here>>>Shares of Elevance Health have returned -4.8% over the past month versus the Zacks S&P 500 composite's -8.9% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Elevance Health, Inc. (ELV): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks